Downregulation of miR-20a-5p is accompanied by upregulation of one of its targets, CD36 (CD36 molecule), and increased lipid deposition, suggesting novel pathogenesis of non-alcoholic fatty liver disease and a potential therapeutic strategy for metabolic diseases [33]. The gene discussed is CD36; the disease is metabolic dysfunction-associated steatotic liver disease.